Ciox Breaks New Ground with Digital Patient Clone™

Publish Date
February 11, 2019

New product to provide real world data to fuel clinical trial management

ALPHARETTA, GA – February 11, 2019 – Ciox, a leading health technology company, today announces the development of the Digital Patient Clone™, a new, research-based health data repository. Currently in limited release with select partners, the Digital Patient Clone will deliver de-identified real world data (RWD). The data available in the Digital Patient Clone will help pharmaceutical and biotech companies employ real world evidence (RWE) to advance their scientific and commercial agendas and bring innovative therapies to patients.

Ciox’s network spans approximately 60 percent of the nation’s hospitals, so the company is well positioned to support the delivery of high-fidelity consented data from a wide variety of structured and unstructured sources. In the life sciences market, Ciox is building a more comprehensive, effective and economical research model, powered by the rich content often buried within the unstructured data in medical records, such as physician notes and patient-reported outcomes.

Oncology researchers require broad and deep data about relevant patients to improve study recruitment, monitor safety appropriately, improve dosing and identify novel indications. Today, more than 700 research organizations have at least one therapy in late-stage development, and most of the largest pharmaceutical companies have dedicated at least one-third of their late-stage R&D activity to oncology. By giving researchers a lens into how a therapy will perform in a highly variable and uncontrolled environment, RWD helps bring more targeted drugs to market quickly and with fewer adverse events.

“Our mission is to help pharmaceutical organizations execute vital data-driven analyses by rapidly and securely sharing the right health information at the right time,” said Julie Krommenhoek, vice president of life sciences, Ciox. “The digital manifestation of a patient in the U.S. is often created in fragments and dispersed across the health care system. The Digital Patient Clone brings disparate data together and, in doing so, enables researchers to make well-informed clinical decisions using real data.”

In the life sciences market, Ciox has long demonstrated the ability to serve clients by gathering clinical data compiled over a multi-year period. For example, Ciox abstracted and coded RWD spanning six or more reported outcomes intervals over the course of eight years for the National Lung Screening Trial, one of the largest screening trials in the U.S. The company has established its expertise within a large set of therapeutic areas supporting RWD requirements for clinical trials, drug safety studies, and health economics and outcomes research.

“At Ciox, we recognize how important it is to improve the speed and precision with which large pharmaceutical companies can quickly and economically obtain analysis-ready clinical data,” said Florian Quarre, chief digital officer, Ciox. “The ability to digitally access a trusted, centralized source of health information and view the complete patient journey is essential to developing the insights needed to support scientific excellence and life-saving therapies for patients around the world.”

About Digital Patient Clone

The Digital Patient Clone contains clinical information, aggregated from consented health data and gathered in a compliant fashion to protect patients’ consent, privacy and anonymity. The focus of the product is to curate the information and link different elements of a patient’s health journey from a wide variety of sources. It offers structured, standardized real world data that can be queried. From that data, it generates real world evidence and provides support in an ongoing, iterative approach to validating hypotheses and identifying cures.

Media Contact
No items found.

Achieve your boldest ambitions

Explore how Datavant can be your health data logistics partner.

Contact us